September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Adaptive Optics Scanning Laser Ophthalmoscopy (AOSLO) in Patients with Central Retinal Vein Occlusion (CRVO) and Cystoid Macular Edema (CME): A SCORE2 Ancillary Study
Author Affiliations & Notes
  • Shane Griffin
    Department of Ophthalmology , University of California San Francisco, San Francisco, California, United States
  • Austin Roorda
    School of Optometry and Vision Science Graduate Group, University of California at Berkeley, Berkeley, California, United States
  • Mina M Chung
    Flaum Eye Institute, Center for Visual Science, University of Rochester, Rochester, New York, United States
  • Hongxin Song
    Flaum Eye Institute, Center for Visual Science, University of Rochester, Rochester, New York, United States
  • Joseph Carroll
    Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
  • Jessica Ijams Wolfing Morgan
    Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Toco Y.P. Chui
    Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States
    Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Richard B Rosen
    Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States
  • Barbara A Blodi
    Department of Opthalmology and Visual Sciences, University of Wisconsin Madison, Madison , Wisconsin, United States
  • Ingrid U Scott
    Hershey Eye Center, Penn State, Hershey, Pennsylvania, United States
  • Jacque L. Duncan
    Department of Ophthalmology , University of California San Francisco, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Shane Griffin, None; Austin Roorda, Canon, Inc (F), University of Houston (P), University of Rochester (P); Mina Chung, Canon Inc. (F), Glaxo Smith Kline (C); Hongxin Song, None; Joseph Carroll, AGTC (F), Optovue, Inc. (F); Jessica Morgan, Canon Inc. (F), US Patent 8226236 (P); Toco Y.P. Chui, None; Richard Rosen, Advanced Cellular Technologies (C), Allergan (C), Carl Zeiss Meditech (C), Clarity (C), Genentech (C), NanoRetina (C), OD-OS (C), Opticology (C), Optovue (C), Regeneron (C); Barbara Blodi, None; Ingrid Scott, None; Jacque Duncan, None
  • Footnotes
    Support  SCORE2 grant: U10EY023533, NIH Grant EY023591, NIH Grant EY014375, NIH Grant EY002162, FDA R01-41001, Research to Prevent Blindness, The Bernard A. Newcomb Macular Degeneration Fund, That Man May See, Inc., Hope for Vision, Foundation Fighting Blindness, 2012 Beckman Initiative for Macular Research Grant 1201
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4170. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Shane Griffin, Austin Roorda, Mina M Chung, Hongxin Song, Joseph Carroll, Jessica Ijams Wolfing Morgan, Toco Y.P. Chui, Richard B Rosen, Barbara A Blodi, Ingrid U Scott, Jacque L. Duncan; Adaptive Optics Scanning Laser Ophthalmoscopy (AOSLO) in Patients with Central Retinal Vein Occlusion (CRVO) and Cystoid Macular Edema (CME): A SCORE2 Ancillary Study. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4170.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To study photoreceptor structure using high resolution imaging techniques in patients with CRVO and CME who enrolled in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE 2).

Methods : Patients were evaluated with AOSLO at one of five study sites. Inclusion criteria included clear natural lenses, pupils that dilate to at least 7 mm in both eyes, 6 diopters myopia or less in both eyes, and reproducible baseline AOSLO images at 2 baseline imaging sessions performed no more than 15 days after the baseline SCORE2 study visit, at which the study eye was randomized to receive a single intravitreal injection of either aflibercept 2mg or bevacizumab 1.25mg. Exclusion criteria included corneal opacification or lack of optical clarity in either eye, refractive surgery in either eye, unstable fixation in either eye, severe hearing disabilities in both ears, dry eye in either eye, and pseudophakia in the diseased eye precluding successful AOSLO baseline imaging. For each baseline montage, 10 regions of interest (ROI) were selected by a single investigator (AR) where at least 50 cones could be counted reliably. Cone spacing, cone density, and cone packing will be assessed at each of the ROIs by 5 independent graders (one from each of the 5 sites). Additional AOSLO imaging is planned at 6 months and 12 months after the baseline imaging date.

Results : CME posed significant challenges to AOSLO image acquisition during baseline imaging sessions. Of the 8 SCORE2 participants evaluated, AOSLO montages showed at least 10 ROIs at both baseline imaging sessions in only 3 patients. In these 3 patients, baseline images showed edema with fluid obscuring photoreceptor detail in many locations within 2.5 degrees of the foveal center, but at least 10 ROIs were identified with quantifiable cones in both baseline montages. Low image quality resulted in 5 screen failures where no cone structure could be discriminated.

Conclusions : CME obscures photoreceptor details in many locations in images acquired using AOSLO after a single intravitreal anti-VEGF treatment in eyes with CRVO. However, cone structures were visualized in a subset of imaged patients, enabling assessment of cone photoreceptor structure in response to anti-VEGF treatment of CME longitudinally.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×